BTIG Maintains Buy on Apogee Therapeutics, Raises Price Target to $128

Benzinga · 4d ago
BTIG analyst Julian Harrison maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $115 to $128.